Latest (89) Full Text Articles (1570) Focus on Nutrition Article Summary

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
Gastroenterology, 01/24/2014  Clinical Article

Zeuzem S, et al. – The authors performed a phase IIb, randomized, double–blind, placebo–controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon–α2a (PegIFN), and ribavirin (RBV) in patients with hepatitis C virus (HCV) genotype–1 infection previously treated with PegIFN and RBV. In treatment–experienced patients, 12, 24, or 48 weeks simeprevir (100 mg or 150 mg once daily) in combination with 48 weeks PegIFN and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, and RBV and was generally well tolerated.


  • The authors analyzed data from patients who did not respond (null response), had a partial response, or relapsed after treatment with PegIFN and RBV, randomly assigned to receive simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks (n = 396), or placebo plus PegIFN and RBV for 48 weeks (n = 66).
  • All patients were followed for 24 weeks after planned end of treatment; the primary end point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA) at that time point.


  • Overall, rates of SVR at 24 weeks were significantly higher in the groups given simeprevir than those given placebo (61%-80% vs 23%; P < .001), regardless of prior response to PegIFN and RBV (simeprevir vs placebo: prior null response, 38%-59% vs 19%; prior partial response, 48%-86% vs 9%; prior relapse, 77%-89% vs 37%).
  • All groups had comparable numbers of adverse events; these led to discontinuation of simeprevir or placebo and/or PegIFN and RBV in 8.8% of patients given simeprevir and 4.5% of those given placebo.

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from PDR - powered by MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top Articles of 2014

1 Detox diets for toxin elimination and weight management: a critical review of the evidence Journal of Human Nutrition and Dietetics, December 19, 2014    Review Article

2 Vitamin D status is associated with intestinal inflammation as measured by fecal calprotectin in Crohn's disease in clinical remission Digestive Diseases and Sciences, March 13, 2015    Clinical Article

3 Consumption of beer and colorectal cancer incidence: A meta-analysis of observational studies Cancer Causes and Control, March 3, 2015    Evidence Based Medicine    Review Article    Clinical Article

4 Dietary intake of flavonoids and oesophageal and gastric cancer: Incidence and survival in the United States of America (USA) British Journal of Cancer, February 20, 2015    Clinical Article

5 Azathioprine discontinuation earlier than 6 months in Crohn’s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation European Journal of Gastroenterology & Hepatology, March 11, 2015    Clinical Article

6 Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin Journal of Gastroenterology, March 2, 2015    Clinical Article

7 Applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis Alimentary Pharmacology and Therapeutics, March 26, 2015    Review Article    Clinical Article

8 Cytomegalovirus and inflammatory bowel disease Alimentary Pharmacology and Therapeutics, February 24, 2015    Review Article

9 A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS The American Journal of Gastroenterology, March 6, 2015    Evidence Based Medicine    Clinical Article

10 Corticosteroid therapy in ulcerative colitis Full Text World Journal of Gastroenterology, March 24, 2015    Free full text    Review Article

11 The safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive Alimentary Pharmacology and Therapeutics, March 9, 2015    Review Article

12 New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease Alimentary Pharmacology and Therapeutics, March 18, 2015    Clinical Article

13 Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial Gut, January 14, 2015    Clinical Article

14 The dirty side of soap UC San Diego Health System, November 19, 2014

15 Budesonide foam induces remission in patients with mild-moderate ulcerative proctitis and ulcerative proctosigmoiditis Gastroenterology, February 6, 2015    Clinical Article

16 The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: The ATLAS study Gut, March 10, 2015    Clinical Article

17 Appearance of hepatobiliary diseases in a population based cohort with inflammatory bowel diseases (ICURE) Journal of Gastroenterology and Hepatology, March 24, 2015

18 Crohn's disease management after intestinal resection: a randomised trial The Lancet, January 7, 2015    Evidence Based Medicine    Clinical Article

19 Clinical practice guidelines for the medical management of non-hospitalized ulcerative colitis: The Toronto Consensus Gastroenterology, March 16, 2015    Clinical Guideline    Clinical Article

20 Predictive factors for the diagnosis of irritable bowel syndrome in a large cohort of 440,822 young adults Journal of Clinical Gastroenterology, March 9, 2015    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Register now to view all our site's content (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from our site and our sponsors
View Samples and Register